Proteomics in diabetic nephropathy

Hyun Jung Kim; Hyun Syuk Yoo; Chan Wha Kim

doi:10.1002/prca.200780062

Proteomics in diabetic nephropathy

Hyun Jung Kim, Hyun Syuk Yoo, Chan Wha Kim

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

Original language	English
Pages (from-to)	301-311
Number of pages	11
Journal	Proteomics - Clinical Applications
Volume	2
Issue number	3
DOIs	https://doi.org/10.1002/prca.200780062
Publication status	Published - 2008 Mar

Keywords

2-D PAGE
Biomarker
Protein marker discovery

ASJC Scopus subject areas

Clinical Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/prca.200780062

Cite this

@article{ddb7e240567941fc8bc92a6c6e820f0e,

title = "Proteomics in diabetic nephropathy",

abstract = "Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.",

keywords = "2-D PAGE, Biomarker, Protein marker discovery",

author = "Kim, {Hyun Jung} and Yoo, {Hyun Syuk} and Kim, {Chan Wha}",

year = "2008",

month = mar,

doi = "10.1002/prca.200780062",

language = "English",

volume = "2",

pages = "301--311",

journal = "Proteomics - Clinical Applications",

issn = "1862-8346",

publisher = "Wiley-VCH Verlag",

number = "3",

}

TY - JOUR

T1 - Proteomics in diabetic nephropathy

AU - Kim, Hyun Jung

AU - Yoo, Hyun Syuk

AU - Kim, Chan Wha

PY - 2008/3

Y1 - 2008/3

N2 - Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

AB - Diabetes mellitus (DM) is currently one of the principal causes of end stage renal disease (ESRD). Approximately 40% of all diabetic patients eventually develop diabetic nephropathy (DN). The complexity of diabetes and its complications require a broad-based, unbiased, scientific approach, such as proteomics, in order to understand the progression of DN. Proteomic techniques have been applied extensively to explore the complexity of the mechanisms associated with DN, and to identify novel biomarkers and therapeutic targets. This review provides insights into how proteomics can be applied to DN, and how experimental data can be linked to clinical applications. In addition, recent proteome studies of DN are summarized. The rapid rate of development of the relevant technologies, along with the combination of classic physiological and biochemical techniques with proteomics will facilitate new discoveries.

KW - 2-D PAGE

KW - Biomarker

KW - Protein marker discovery

UR - http://www.scopus.com/inward/record.url?scp=41149088788&partnerID=8YFLogxK

U2 - 10.1002/prca.200780062

DO - 10.1002/prca.200780062

M3 - Review article

C2 - 21136835

AN - SCOPUS:41149088788

SN - 1862-8346

VL - 2

SP - 301

EP - 311

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

IS - 3

ER -

Proteomics in diabetic nephropathy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this